Desirability and feasibility of a vaccine against cytomegalovirus

► The burden of disease attributable to CMV is high. ► CMV has been assumed to be a formidable target for vaccinologists. ► Laboratory measures of CMV infection have been defined as candidate endpoints for vaccine trials. ► Three recent randomised controlled trials have reported encouraging results. ► CMV may become a vaccine preventable infection.